FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383619854> ?p ?o ?g. }

• W4383619854 abstract "Abstract Background Despite advances in treatment, recurrence and mortality rates from breast cancer (BrCa) continue to rise, clinical effectiveness is limited, and prognosis remains disappointing, especially for patients with HER2-positive, triple-negative, or advanced breast cancer. Based on cuproptosis-related long noncoding RNAs (CRLs), this study aims to create a predictive signature to assess the prognosis in patients with BrCa. Methods The related CRLs RNA-seq data clinicopathological data were collected from The Cancer Genome Atlas (TCGA) database, and the predictive model was constructed after correlation analysis. Subsequently, we examined and validated connections and changes in the CRLs model with prognostic features (including risk curves, ROC curves and nomograms), pathway and functional enrichment, tumor mutation (TMB), tumor immune dysfunction and exclusion (TIDE) and treatment sensitivity. Results A prediction model formula composed of 5 CRLs was obtained, and divided breast cancer patients into high and low risk subgroups according to the obtained risk scores. The results showed that the overall survival (OS) of patients in the high-risk group was lower than that in the low-risk group, and the AUC of all samples at 1, 3 and 5 years were 0.704, 0.668 and 0.647, respectively. It was indicated that CRLs prognostic model could independently predict prognostic indicators of BrCa patients. In addition, analysis of gene set enrichment, immune function, TMB, and TIDE showed that these differentially expressed CRLs had a wealth of related pathways and functions, and might be closely related to immune response and immune microenvironment. Additionally, TP53 was found to have the highest mutation frequency in high-risk group (40%), while PIK3CA was found to have the highest mutation frequency in low-risk group (42%), which might become new targets for targeted therapy. Finally, we compared susceptibility to anticancer agents to identify potential treatment options for breast cancer. Lapatinib, Sunitinib, Phenformin, Idelalisib, Ruxolitinib, Cabozantinib were more sensitive to patients in the low-risk group, while Sorafenib, Vinorelbine, Pyrimethamine were more sensitive to patients in high-risk group, namely, these drugs could potentially be used in the future to treat breast cancer patients grouped according to the risk model. Conclusion This study identified CRLs associated with breast cancer and provided a tailored tool for predicting prognosis, immune response, and drug sensitivity in patients with BrCa." @default.
• W4383619854 created "2023-07-09" @default.
• W4383619854 creator A5034711601 @default.
• W4383619854 creator A5082618564 @default.
• W4383619854 date "2023-07-08" @default.
• W4383619854 modified "2023-09-25" @default.
• W4383619854 title "Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer" @default.
• W4383619854 cites W1966682269 @default.
• W4383619854 cites W1986705163 @default.
• W4383619854 cites W1997183854 @default.
• W4383619854 cites W2018663224 @default.
• W4383619854 cites W2068205741 @default.
• W4383619854 cites W2074747472 @default.
• W4383619854 cites W2075294566 @default.
• W4383619854 cites W2079831587 @default.
• W4383619854 cites W2141563900 @default.
• W4383619854 cites W2158025958 @default.
• W4383619854 cites W2272984102 @default.
• W4383619854 cites W2528388077 @default.
• W4383619854 cites W2549441121 @default.
• W4383619854 cites W2747016053 @default.
• W4383619854 cites W2748551035 @default.
• W4383619854 cites W2790455265 @default.
• W4383619854 cites W2792951836 @default.
• W4383619854 cites W2890087043 @default.
• W4383619854 cites W2902415760 @default.
• W4383619854 cites W2932887409 @default.
• W4383619854 cites W2964233401 @default.
• W4383619854 cites W2972758365 @default.
• W4383619854 cites W3002154893 @default.
• W4383619854 cites W3025589456 @default.
• W4383619854 cites W3082257632 @default.
• W4383619854 cites W3089208497 @default.
• W4383619854 cites W3128646645 @default.
• W4383619854 cites W3142080073 @default.
• W4383619854 cites W3194302859 @default.
• W4383619854 cites W3205973818 @default.
• W4383619854 cites W3206960301 @default.
• W4383619854 cites W4211032970 @default.
• W4383619854 cites W4220817961 @default.
• W4383619854 cites W4221115671 @default.
• W4383619854 cites W4286488841 @default.
• W4383619854 cites W4288698320 @default.
• W4383619854 cites W4289731219 @default.
• W4383619854 cites W4296445148 @default.
• W4383619854 cites W4297239225 @default.
• W4383619854 cites W4313655771 @default.
• W4383619854 doi "https://doi.org/10.1186/s12920-023-01590-z" @default.
• W4383619854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37422644" @default.
• W4383619854 hasPublicationYear "2023" @default.
• W4383619854 type Work @default.
• W4383619854 citedByCount "0" @default.
• W4383619854 crossrefType "journal-article" @default.
• W4383619854 hasAuthorship W4383619854A5034711601 @default.
• W4383619854 hasAuthorship W4383619854A5082618564 @default.
• W4383619854 hasBestOaLocation W43836198541 @default.
• W4383619854 hasConcept C104317684 @default.
• W4383619854 hasConcept C121608353 @default.
• W4383619854 hasConcept C126322002 @default.
• W4383619854 hasConcept C143998085 @default.
• W4383619854 hasConcept C203014093 @default.
• W4383619854 hasConcept C34626388 @default.
• W4383619854 hasConcept C530470458 @default.
• W4383619854 hasConcept C54355233 @default.
• W4383619854 hasConcept C58471807 @default.
• W4383619854 hasConcept C60644358 @default.
• W4383619854 hasConcept C62203573 @default.
• W4383619854 hasConcept C67705224 @default.
• W4383619854 hasConcept C71924100 @default.
• W4383619854 hasConcept C86803240 @default.
• W4383619854 hasConcept C8891405 @default.
• W4383619854 hasConceptScore W4383619854C104317684 @default.
• W4383619854 hasConceptScore W4383619854C121608353 @default.
• W4383619854 hasConceptScore W4383619854C126322002 @default.
• W4383619854 hasConceptScore W4383619854C143998085 @default.
• W4383619854 hasConceptScore W4383619854C203014093 @default.
• W4383619854 hasConceptScore W4383619854C34626388 @default.
• W4383619854 hasConceptScore W4383619854C530470458 @default.
• W4383619854 hasConceptScore W4383619854C54355233 @default.
• W4383619854 hasConceptScore W4383619854C58471807 @default.
• W4383619854 hasConceptScore W4383619854C60644358 @default.
• W4383619854 hasConceptScore W4383619854C62203573 @default.
• W4383619854 hasConceptScore W4383619854C67705224 @default.
• W4383619854 hasConceptScore W4383619854C71924100 @default.
• W4383619854 hasConceptScore W4383619854C86803240 @default.
• W4383619854 hasConceptScore W4383619854C8891405 @default.
• W4383619854 hasIssue "1" @default.
• W4383619854 hasLocation W43836198541 @default.
• W4383619854 hasLocation W43836198542 @default.
• W4383619854 hasLocation W43836198543 @default.
• W4383619854 hasOpenAccess W4383619854 @default.
• W4383619854 hasPrimaryLocation W43836198541 @default.
• W4383619854 hasRelatedWork W2120603712 @default.
• W4383619854 hasRelatedWork W2168316764 @default.
• W4383619854 hasRelatedWork W2224319365 @default.
• W4383619854 hasRelatedWork W3041643115 @default.
• W4383619854 hasRelatedWork W3093526768 @default.
• W4383619854 hasRelatedWork W3200895526 @default.
• W4383619854 hasRelatedWork W3216330551 @default.
• W4383619854 hasRelatedWork W4363610455 @default.

• next